Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Logothetis

Showing results (21-30 of 251) with videos related to

Pageof 26
Sort By:
European Urology|March 27, 2024
Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7Christopher J Logothetis, Andrew W Hahn
European Urology|May 20, 2023
Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap SyndromeChristopher J Logothetis, Andrew W Hahn
European Urology|October 23, 2010
Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urotheliumChristopher J Logothetis, Arlene Siefker-Radtke
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Informative clinical investigation: a demanding taskmasterEleni Efstathiou, Jeri Kim, Christopher J Logothetis
Cancer Genomics & Proteomics|May 18, 2012
In silico functional profiling of individual prostate cancer tumors: many genes, few functionsIvan P Gorlov, Jinyoung Byun, Christopher J Logothetis
International Journal of Cancer|June 25, 2009
Housekeeping genes in prostate tumorigenesisJinyoung Byun, Christopher J Logothetis, Ivan P Gorlov
Cancer Discovery|May 16, 2012
Understanding the lethal variant of prostate cancer: power of examining extremesAna Aparicio, Christopher J Logothetis, Sankar N Maity
Seminars in Oncology|June 4, 2004
Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancerPaul Mathew, Isaiah J Fidler, Christopher J Logothetis
The Lancet. Oncology|July 31, 2002
Stem-cell origin of metastasis and heterogeneity in solid tumoursShi-Ming Tu, Sue-Hwa Lin, Christopher J Logothetis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Understanding the biology of bone metastases: key to the effective treatment of prostate cancerChristopher J Logothetis, Nora M Navone, Sue-Hwa Lin
Pageof 26

Showing results (21-30 of 251) with videos related to

Sort By:
Pageof 26
European Urology|March 27, 2024
Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7Christopher J Logothetis, Andrew W Hahn
European Urology|May 20, 2023
Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap SyndromeChristopher J Logothetis, Andrew W Hahn
European Urology|October 23, 2010
Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urotheliumChristopher J Logothetis, Arlene Siefker-Radtke
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Informative clinical investigation: a demanding taskmasterEleni Efstathiou, Jeri Kim, Christopher J Logothetis
Cancer Genomics & Proteomics|May 18, 2012
In silico functional profiling of individual prostate cancer tumors: many genes, few functionsIvan P Gorlov, Jinyoung Byun, Christopher J Logothetis
International Journal of Cancer|June 25, 2009
Housekeeping genes in prostate tumorigenesisJinyoung Byun, Christopher J Logothetis, Ivan P Gorlov
Cancer Discovery|May 16, 2012
Understanding the lethal variant of prostate cancer: power of examining extremesAna Aparicio, Christopher J Logothetis, Sankar N Maity
Seminars in Oncology|June 4, 2004
Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancerPaul Mathew, Isaiah J Fidler, Christopher J Logothetis
The Lancet. Oncology|July 31, 2002
Stem-cell origin of metastasis and heterogeneity in solid tumoursShi-Ming Tu, Sue-Hwa Lin, Christopher J Logothetis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Understanding the biology of bone metastases: key to the effective treatment of prostate cancerChristopher J Logothetis, Nora M Navone, Sue-Hwa Lin
Pageof 26